Denmark: Philip Morris International to acquire Fertin Pharma

Tobacco manufacturer Philip Morris International (PMI) has announced the acquisition of Fertin Pharma for DKK 5.1 billion (approximately USD 820 million).

Fertin Pharma is a leading developer and manufacturer of innovative pharmaceutical and well-being products, specializing in the research, development and production of gums, pouches, liquefiable tablets, and other solid oral systems for the delivery of active ingredients, including nicotine. The company has more than 850 employees in its facilities in Denmark, Canada, and India.

“The acquisition of Fertin Pharma will be a significant step forward on our journey toward delivering a smoke-free future—enhancing our smoke-free portfolio, notably in modern oral, and accelerating our progress in beyond nicotine,” said Jacek Olczak, CEO at PMI.

The transaction is expected to be closed in the fourth quarter of 2021, subject to approval by the appropriate regulatory authorities.

Source: Philip Morris International